- Home
- SNDX vs ADEA Comparison
SNDX vs ADEA Comparison
Compare SNDX & ADEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNDX
- ADEA
- Stock Information
- Founded
- SNDX 2005
- ADEA 1990
- Country
- SNDX United States
- ADEA United States
- Employees
- SNDX N/A
- ADEA N/A
- Industry
- SNDX Biotechnology: Pharmaceutical Preparations
- ADEA Computer Software: Prepackaged Software
- Sector
- SNDX Health Care
- ADEA Technology
- Exchange
- SNDX Nasdaq
- ADEA Nasdaq
- Market Cap
- SNDX 1.1B
- ADEA 1.5B
- IPO Year
- SNDX 2016
- ADEA N/A
- Fundamental
- Price
- SNDX $9.00
- ADEA $14.64
- Analyst Decision
- SNDX Strong Buy
- ADEA Strong Buy
- Analyst Count
- SNDX 10
- ADEA 4
- Target Price
- SNDX $35.80
- ADEA $19.50
- AVG Volume (30 Days)
- SNDX 1.8M
- ADEA 562.4K
- Earning Date
- SNDX 07-31-2025
- ADEA 08-05-2025
- Dividend Yield
- SNDX N/A
- ADEA 1.37%
- EPS Growth
- SNDX N/A
- ADEA 89.09
- EPS
- SNDX N/A
- ADEA 0.66
- Revenue
- SNDX $43,722,000.00
- ADEA $380,289,000.00
- Revenue This Year
- SNDX $426.77
- ADEA $10.68
- Revenue Next Year
- SNDX $98.31
- ADEA $4.16
- P/E Ratio
- SNDX N/A
- ADEA $22.18
- Revenue Growth
- SNDX N/A
- ADEA 7.16
- 52 Week Low
- SNDX $8.58
- ADEA $9.68
- 52 Week High
- SNDX $25.07
- ADEA $17.46
- Technical
- Relative Strength Index (RSI)
- SNDX 38.70
- ADEA 66.79
- Support Level
- SNDX $8.77
- ADEA $14.00
- Resistance Level
- SNDX $9.50
- ADEA $13.89
- Average True Range (ATR)
- SNDX 0.53
- ADEA 0.46
- MACD
- SNDX -0.04
- ADEA 0.09
- Stochastic Oscillator
- SNDX 14.13
- ADEA 93.85
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
About ADEA Adeia Inc.
Adeia Inc is a consumer and entertainment product/solutions licensing company. Its only operating segment being Intellectual Property (IP) Licensing. In the IP segment, it primarily license innovations to leading companies in the broader entertainment industry, and those developing new technologies that will help drive this industry forward. It includes Pay-TV, Consumer Electronics, Connected Car, and Media Platform.